DISC-0974

DISC-0974 is Disc Medicine's antibody targeting hemojuvelin (HJV), a co-receptor that amplifies signals telling the liver to make hepcidin - the hormone that locks iron away from red blood cell production. By blocking HJV, the drug aims to lower hepcidin and free iron for new red blood cells in patients whose anemia is driven by chronic inflammation. The company is running it across three indications in parallel: IBD-associated anemia (RALLY-IBD Phase 2, NCT07368972) [2], myelofibrosis-related anemia (Phase 1b/2 RALLY-MF, NCT05320198) [3], and non-dialysis CKD anemia (Phase 1b completed, NCT05745883) [4]. This matters commercially because anemia of inflammation is a large underserved population - IV iron doesn't fix it because the iron gets locked away, and erythropoiesis-stimulating agents (ESAs) carry cardiovascular boxed warnings and work poorly when hepcidin is high. The Phase 2 IBD trial enrolling 21 patients with primary endpoint of hemoglobin change through Day 85 will give an early efficacy read. Disc Medicine (IRON) is best known for bitopertin in erythropoietic protoporphyria; DISC-0974 is the company's main pipeline optionality and the asset most likely to re-rate the stock if the myelofibrosis data lands clean [5].

DISC-0974 is a novel first-in-class anti-HJV monoclonal antibody with no other anti-hemojuvelin biologics in clinical development. The IBD Phase 2 (NCT07368972, DISC-0974-201, branded RALLY-IBD) is sponsored entirely by Disc Medicine with no disclosed development partner; the trial was posted to ClinicalTrials.gov 2026-05-04 with a target enrollment of 21 patients [2]. No FDA designations (breakthrough, fast track, orphan, RMAT) have been publicly disclosed for the IBD program. Disc has not announced breakthrough or fast track for the RALLY-MF Phase 1b/2 either, though the myelofibrosis cohort enrolls patients with limited options and would be a candidate for orphan designation if the company pursues it. The first-in-human Phase 1 in healthy volunteers (NCT04999527, Novikov et al. J Clin Pharmacol 2024) showed dose-dependent reductions in serum hepcidin and corresponding increases in serum iron [1][6]. The completed Phase 1b in non-dialysis CKD patients (NCT05745883) reported at ASN Kidney Week 2024 dose-dependent hepcidin suppression and increases in serum iron, transferrin saturation, reticulocyte hemoglobin, and total hemoglobin versus placebo, with no safety signals disclosed that would derail further development [4][9]. Disc's 8-K filings from October 2025, February 2026, and May 2026 contain corporate and pipeline updates [7]. Expected Phase 2 IBD readout is likely late 2026 to 2027 given the Day 85 primary endpoint and current recruitment status. The RALLY-MF readout, which Disc has positioned as the more commercially significant milestone, is the catalyst public materials point investors toward in 2026 (interim data expected H2 2026 per company commentary) [5].

Hepcidin is the body's iron thermostat. When it goes up, dietary iron stays trapped in gut cells and iron stored in macrophages stays locked away, starving red blood cell production. In chronic inflammation - IBD, CKD, cancer, myelofibrosis - inflammatory cytokines push hepcidin sky-high, creating functional iron deficiency even when total body iron is plenty. This is anemia of inflammation, and current options are bad. IV iron gets absorbed but then re-sequestered. ESAs like erythropoietin struggle to drive red cell production when iron is locked up. Hepcidin transcription in the liver is driven primarily by BMP6 (a bone morphogenetic protein) signaling through a receptor complex on hepatocytes. Hemojuvelin (HJV) is the co-receptor that turbocharges this signal; without HJV, BMP6 binds weakly and hepcidin production drops [8]. DISC-0974 is a monoclonal antibody that blocks HJV, breaking the BMP6 amplification step and lowering hepcidin output. The genetic case for this target is strong. People born with loss-of-function HJV mutations develop juvenile hemochromatosis, a severe iron overload disease caused by chronically low hepcidin [8]. That's a clean human knockout phenotype showing exactly what blocking HJV does. The Phase 1 healthy volunteer data confirmed the pharmacology: single doses produced sustained hepcidin suppression and rising serum iron [1]. The CKD Phase 1b extended this further, showing the hepcidin-lowering effect translates to actual hemoglobin and reticulocyte gains in patients with anemia of inflammation [9]. So the mechanism is biologically real, human-validated, and now demonstrated to move the clinical endpoint that matters. The remaining question isn't whether DISC-0974 lowers hepcidin or raises hemoglobin in CKD (it does both) but whether the effect size in IBD and MF is large enough to clear approval and reimbursement hurdles, and whether long-term dosing avoids iron overload toxicity.

The IBD trial (NCT07368972, DISC-0974-201, RALLY-IBD) is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study with an enrollment target of 21 participants with active inflammatory bowel disease and anemia of inflammation [2]. Primary endpoint is maximal change from baseline in hemoglobin through Day 85. That's a short, biomarker-style readout for a Phase 2 - not a clinical outcome trial, more a proof-of-concept study before committing capital to a Phase 2b or Phase 3. The small n=21 is defensible for detecting a strong Hgb signal given the placebo-controlled design and within-patient variability. The Day 85 timepoint is reasonable for an antibody with extended half-life and gives time for erythropoiesis to respond once iron becomes available. The concern is what comes next. Twenty-one patients won't be enough to power subgroup analyses or characterize safety beyond gross signals. The trial also does not appear to pre-stratify patients by baseline hepcidin or inflammation markers, which is a missed opportunity for a mechanism-targeted drug. The parallel RALLY-MF trial (NCT05320198) enrolls up to ~150 patients and includes a Phase 1b dose-finding portion followed by Phase 2 expansion in myelofibrosis and myelodysplastic syndromes (MDS) patients with anemia, with treatment-emergent adverse events as the Phase 1b primary endpoint [3]. Initial Phase 1b data in MF patients were presented at ASH 2024 (n≈30) showing hemoglobin gains and reduced transfusion burden in a subset [10]. That trial is where Disc has stated the more commercially significant readout will come. Both trials use Disc Medicine as sponsor with no co-development partner publicly disclosed.

Our model gives this drug a 5% chance of eventually being approved. That starts from a historical baseline of about 30% for Phase 2 drugs in this area, then adjusts based on ten facts about the trial and sponsor. The estimate is pulled down mainly by the sponsor's thin approval record, heavier-than-usual blinding, and weak earlier-phase results - though having more secondary endpoints than usual pushes it in the other direction. The remaining factors are close to average for this stage and don't move the number much.

Efficacy risk is the dominant concern. Lowering hepcidin reliably raises serum iron, but turning that into a clinically meaningful Hgb gain in patients with active inflammation, ongoing blood loss, and disease-driven RBC suppression is a separate question. In IBD specifically, GI blood loss can outpace iron mobilization, and a modest Hgb gain over placebo (say, 0.5 to 1.0 g/dL) is a signal but not a slam-dunk versus IV iron plus cheaper interventions. Safety risk centers on iron overload. The human knockout phenotype (juvenile hemochromatosis) is severe iron overload causing cardiac and endocrine failure [8]. Chronic dosing of DISC-0974 essentially partial-knocks-out the same pathway. Sub-chronic dosing studies haven't shown overload to date [1][4], but a multi-year therapy in CKD or MF patients could accumulate hepatic and cardiac iron in ways short trials won't catch. Disc will need to monitor ferritin and transferrin saturation carefully across all programs. Execution risk: the IBD trial's n=21 means a single non-responder cluster could mask a real effect. Disc is running three indications in parallel, but the cash position is strong - full-year 2025 results disclosed $791M cash and securities with runway stated into 2029 against R&D of ~$171M and net loss of ~$212M for 2025 [5][7]. That removes near-term financing pressure as a forced-prioritization risk and gives the company room to run all three indications through readouts. Commercial risk: if approved, payers will compare against IV iron (cheap, generic) and ESAs (off-patent biosimilars). An anti-HJV antibody will price as a biologic. The reimbursement case requires a population where current therapies clearly fail. CKD anemia in particular faces competition from oral HIF prolyl hydroxylase inhibitors (HIF-PHIs - roxadustat, vadadustat, daprodustat), which lower hepcidin downstream through a different mechanism. In myelofibrosis, the most direct competitor is luspatercept (Reblozyl, Bristol Myers Squibb/Acceleron), approved for low-risk MDS anemia and beta-thalassemia and tested in MF in the Phase 3 INDEPENDENCE trial; that trial missed its primary endpoint of 12-week RBC transfusion independence on top of Janus kinase (JAK) inhibitors but showed numerical and clinically meaningful improvements on secondary endpoints [11]. The mixed luspatercept readout is actually a tailwind for DISC-0974 - it shows MF anemia remains an unmet need that a mechanistically distinct hepcidin-lowering antibody could fill.

Worth watching, with the caveat that the IBD Phase 2 isn't the readout that matters most. The signal that would change the picture is the RALLY-MF Phase 1b/2 data in myelofibrosis-associated anemia [3]. That's a population where ESAs fail, current options are weak, and the commercial opportunity is real because MF patients are on Janus kinase (JAK) inhibitors (ruxolitinib, fedratinib) that often worsen anemia. Disc has positioned MF as the lead indication for a reason: orphan-drug economics with a clear unmet need and a price tag that works for a biologic. Luspatercept's INDEPENDENCE trial miss in the same setting [11] arguably opens the door wider for DISC-0974 if the RALLY-MF expansion data show a cleaner transfusion-independence signal. Check back when Disc reports RALLY-MF interim data, which the company has framed as a 2026 catalyst in recent investor materials [5][7]. The IBD Phase 2 readout (likely late 2026 to 2027 given the Day 85 endpoint and current recruitment of 21 patients) is a secondary watchpoint, useful for inflammation proof-of-concept but less commercially significant than MF. Disc Medicine (IRON) trades primarily on bitopertin in erythropoietic protoporphyria, with DISC-0974 providing pipeline optionality. The balance sheet ($791M, runway into 2029) means a clean MF anemia signal would re-rate the stock without immediate dilution overhang. A miss in IBD wouldn't kill the program but would shift focus toward MF and CKD. The biology is solid and human-validated; patient selection, durability of effect, head-to-head positioning against luspatercept in MF, and long-term iron overload risk are the open questions that will decide whether DISC-0974 becomes a real drug or an interesting failed mechanism.